Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
نویسندگان
چکیده
منابع مشابه
dysphagia in acute ischemic stroke
Introduction: Swallowing dysfunction complicates acute strokes in 25-32% of cases and directly affects patientschr('39') prognosis and recovery. Dysphagia complicates the course of acute strokes through its potential of the development of chest infection, nutritional problems, and dehydration. Dysphagia is also an independent predictor of respiratory morbidity and mortality in acute stroke. In...
متن کاملThrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital
INTRODUCTION Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase. METHODS We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute is...
متن کاملTissue Engineering of the Trachea: What is the Hold-up?
Tissue-engineering of the trachea is called for based on the clinical consequences of airway pathology. Recent years have witnessed various reports from the tissueengineering field including a few cases of clinical patients receiving an engineered airway. Multiple fields have accelerated in parallel with the concept of tissue decellularization, isolation of stem cells and possible insights in t...
متن کاملO10: Thrombo-Inflammation in Acute Ischemic Stroke
Ischemic stroke has been classified as a merely thrombotic disease, so the main goal of its treatment is the recanalization of the occluded vasculature. However, despite fast restoration of blood circulation, progressive stroke still develops in many patients, which has led to the concept of reperfusion injury. The underlying mechanism is only partly known. Though, it is accepted now, tha...
متن کاملA randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Western Journal of Emergency Medicine
سال: 2020
ISSN: 1936-900X
DOI: 10.5811/westjem.2020.1.45279